Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Major lumbar spine surgery causes inflammation, soreness and swelling that can delay discharge from the hospital. Dexmedetomidine (DEX) has been shown to have anti-inflammatory effects. This study will evaluate whether DEX can help get patients out of the hospital faster after major spine surgery by reducing the inflammation associated with the procedure itself. A separate part of the study will evaluate the blood levels of some specific indicators of inflammation called cytokines. Measuring cytokines before and after surgery will aid in determining if DEX has altered the inflammatory response.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) Classification I - III

• Scheduled for Open Posterior Lumbar Fusion over 3+ (bony) levels

Exclusion Criteria:

• Allergy to dexmedetomidine

• Cardiac disease with reduced ejection fraction < 30%

• History of cirrhosis, active hepatitis or attenuated hepatic function

• Chronic use of steroids, COX-2 inhibitors, alpha-2 agonists, or statins

• Current anticoagulant therapy

• Patients requiring motor evoked potential (MEP) monitoring

• Positive pregnancy test